Inspire Medical Systems (NYSE: INSP)+ announced today that it received FDA approval for its Inspire V therapy system.

Inspire V includes a next-generation neurostimulator and associated Bluetooth patient remote and physician programmer. It marks the latest innovation for the Minneapolis-based obstructive sleep apnea (OSA) treatment developer.

The pacemaker-like device delivers mild electrical stimulation to the hypoglossal nerve, which controls tongue muscles.